Keywords: فسفودی استراز 4; atopic dermatitis; crisaborole; eczema; long-term safety; ointment; PDE4; phosphodiesterase-4; topical treatment; AD; atopic dermatitis; AE; adverse event; ISGA; Investigator's Static Global Assessment; PDE4; phosphodiesterase-4; SAE; serious adverse even
مقالات ISI فسفودی استراز 4 (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Rates of escalation to triple COPD therapy among incident users of LAMA and LAMA/LABA
Keywords: فسفودی استراز 4; Combination therapy; COPD; Inhaled corticosteroids; Long-acting bronchodilators; LAMA/LABA; Fixed-dose dual bronchodilators; CDS; Chronic Disease Score; CI; confidence interval; COPD; chronic obstructive pulmonary disease; ER; emergency room; FDC; fixed-d
The phosphodiesterase-4 inhibitor, FCPR16, attenuates ischemia-reperfusion injury in rats subjected to middle cerebral artery occlusion and reperfusion
Keywords: فسفودی استراز 4; Bax; Bcl-2 associated x protein; Bcl-2; B-cell lymphoma-2; cAMP; cyclic adenosine monophosphate; CNS; central nervous system; CREB; cAMP-response element binding protein; GFAP; glial fibrillary acidic protein; H&E; haematoxylin and eosin; Iba-1; ionized c
Design, synthesis, and biological evaluation of novel catecholopyrimidine based PDE4 inhibitor for the treatment of atopic dermatitis
Keywords: فسفودی استراز 4; Atopic dermatitis; Phosphodiesterase-4; Catecholopyrimidine; Dinitrochlorobenzene; Molecular docking;
The discovery, complex crystal structure, and recognition mechanism of a novel natural PDE4 inhibitor from Selaginella pulvinata
Keywords: فسفودی استراز 4; Phosphodiesterase-4; Natural inhibitor; Selaginpulvilins K; Crystal structure; Recognition mechanism;
Reduced COPD Exacerbation Risk Correlates With Improved FEV1
Keywords: فسفودی استراز 4; COPD exacerbations; COPD mechanisms; COPD pharmacology; BD; bronchodilator; dFEV1; between-group difference in change in predose (trough) FEV1 from the beginning to the end of the trial; HR; hazard ratio; non-BD; nonbronchodilator; PDE4; phosphodiesterase
Discovery and modelling studies of natural ingredients from Gaultheria yunnanensis (FRANCH.) against phosphodiesterase-4
Keywords: فسفودی استراز 4; Phosphodiesterase-4; Gaultheria yunnanensis (FRANCH.); Anti-inflammatory agents
OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild to moderate atopic dermatitis (AD): A phase-II randomized, double-blind, placebo-controlled study
Keywords: فسفودی استراز 4; atopic dermatitis; atopic eczema; OPA-15406; phosphodiesterase type 4 inhibitor; topical agents; topical calcineurin inhibitor; AD; atopic dermatitis; BSA; body surface area; DLQI; Dermatology Life Quality Index; EASI; Eczema Area and Severity Index; IGA;
PDE4 Inhibition as Potential Treatment of Epidermolysis Bullosa Acquisita
Keywords: فسفودی استراز 4; Akt; RAC-alpha serine/threonine-protein kinase; COL7; type VII collagen; EBA; epidermolysis bullosa acquisita; IC; immune complex; MAPK; mitogen-activated protein kinase; PD; pemphigoid disease; PDE4; phosphodiesterase-4; PMA; phorbol 12-myristate 13-acet
Decrease of phosphorylated CREB and ERK in nucleus accumbens is associated with the incubation of heroin seeking induced by cues after withdrawal
Keywords: فسفودی استراز 4; CREB; cAMP response element binding protein; ERK; extracellular regulated protein kinases; PDE4; phosphodiesterase-4; aCSF; arificial cerebrospinal fluid; Addiction; cAMP; Opioid; Phosphodiesterase-4; Transcription factor;
Roflumilast added to triple therapy in patients with severe COPD: AÂ real life study
Keywords: فسفودی استراز 4; COPD exacerbations; Phosphodiesterase-4 inhibitors; Combination therapy; Side effects; AECOPD; acute exacerbation of COPD; ICS; inhaled corticosteroids; LABA; long-acting β-agonist; LAMA; long-acting muscarinic antagonist; PDE-4; phosphodiesterase-4;
The molecular basis for the inhibition of phosphodiesterase-4D by three natural resveratrol analogs. Isolation, molecular docking, molecular dynamics simulations, binding free energy, and bioassay
Keywords: فسفودی استراز 4; Phosphodiesterase-4; Resveratrol analog; Inhibition; Mechanism; Modeling; Bioassay;
Methylxanthines do not affect rhythmogenic preBötC inspiratory network activity but impair bursting of preBötC-driven motoneurons
Keywords: فسفودی استراز 4; C4; fourth cervical; CPA; cyclopiazonic acid; DMPX; 3,7-dimethyl-1-propargylxanthine; DPCPX; 8-cyclopentyl-1,3-dipropylxanthine; Hepes; hydroxyethyl piperazineethanesulfonic acid; IRCs; ictal respiratory changes; P; postnatal day; PDE4; phosphodiesterase-
The type 4 phosphodiesterase inhibitors rolipram and YM976 facilitate recall of the weak version of the passive avoidance task in the day-old chick
Keywords: فسفودی استراز 4; Chick; Phosphodiesterase-4; Rolipram; YM976; Memory; Passive avoidance;
Cilomilast for COPD : Results of a 6-Month, Placebo-Controlled Study of a Potent, Selective Inhibitor of Phosphodiesterase 4
Keywords: فسفودی استراز 4; cilomilast; COPD; phosphodiesterase-4; phosphodiesterase-4 enzymeCI, confidence interval; PDE, phosphodiesterase; SGRQ, St. George’s Respiratory Questionnaire
Effects of ciclamilast, a new PDE 4 PDE4 inhibitor, on airway hyperresponsiveness, PDE4D expression and airway inflammation in a murine model of asthma
Keywords: فسفودی استراز 4; Phosphodiesterase-4; PDE4D; Ciclamilast; Dexamethasone; Inflammation; Cytokines; Goblet cell; Airways hyperresponsiveness; Asthma
Treatments for COPD
Keywords: فسفودی استراز 4; ATS; American Thoracic Society; COPD; chronic obstructive pulmonary disease; CXCR1/CXCR2; chemokine receptors 1 and 2; ERS; European Respiratory Society; FEV1; forced expiratory volume in 1Â s; GOLD; Global Initiative for Chronic Obstructive Lung Disease;
Keynote review: Phosphodiesterase-4 as a therapeutic target
Keywords: فسفودی استراز 4; Pharmaceutical Science; Drug Discovery; Biochemistry; Chemical Biology; Structural Biology; phosphodiesterase-4; rolipram; chronic obstructive pulmonary disease; COPD; asthma; cancer; depression; cyclic AMP;